SCHEMBL1031843

SCHEMBL1031843

O=c1c2c(Cl)cccc2cc(-c2ccc(Br)s2)n1Cc1ccc(F)cc1F

nearest known ligand 0.42

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
RXRA P19793 4/20 0.42
NR1H2 P55055 4/20 0.42
NR1H3 Q13133 4/20 0.42
CHRM5 P08912 1/20 0.38
MAPK14 Q16539 8/20 0.38
PKM P14618 1/20 0.35
PKLR P30613 1/20 0.35
CHRNA7 P36544 1/20 0.35
P2RX7 Q99572 1/20 0.34
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1030533 0.83 RXRA (0.49) RXRANR1H2NR1H3CHRM5MAPK14
SCHEMBL1031492 0.83 RXRA (0.46) RXRANR1H2NR1H3CHRM5MAPK14
SCHEMBL1034200 0.83 RXRA (0.57) RXRANR1H2NR1H3
SCHEMBL1034044 0.81 RXRA (0.46) RXRANR1H2NR1H3MAPK14P2RX7
SCHEMBL1030912 0.81 NR1H2 (0.51) RXRANR1H2NR1H3CHRNA7P2RX7
SCHEMBL1033899 0.80 RXRA (0.45) RXRANR1H2NR1H3MAPK14CHRNA7
SCHEMBL1032287 0.80 RXRA (0.43) RXRANR1H2NR1H3MAPK14CHRNA7
SCHEMBL1032259 0.80 CHRM5 (0.37) RXRANR1H2NR1H3CHRM5MAPK14
SCHEMBL1034194 0.79 RXRA (0.42) RXRANR1H2NR1H3MAPK14P2RX7
SCHEMBL1030550 0.78 RXRA (0.49) RXRANR1H2NR1H3MAPK14CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1572660-B1 ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS X CEPTOR THERAPEUTICS INC (US) 2011-01-26 EP claimed
US-20080132521-A1 Isoquinolinone Derivatives and Their Use As Therapeutic Agents EXELIXIS, INC. (US) 2008-06-05 US claimed
US-7265131-B2 Isoquinolinone derivatives and their use as therapeutic agents EXELIXIS, INC. (US) 2007-09-04 US claimed
EP-1572660-A1 ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS X-Ceptor Therapeutics, Inc. (US) 2005-09-14 EP claimed
US-20040204447-A1 Isoquinolinone derivatives and their use as therapeutic agents X-CEPTOR THERAPEUTICS INC. 2004-10-14 US claimed
WO-2004058717-A1 ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS X-CEPTOR THERAPEUTICS, INC. (US) 2004-07-15 WO claimed
EP-1572660-B1 ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS X CEPTOR THERAPEUTICS INC (US) 2011-01-26 EP disclosed
US-20080132521-A1 Isoquinolinone Derivatives and Their Use As Therapeutic Agents EXELIXIS, INC. (US) 2008-06-05 US disclosed
US-7265131-B2 Isoquinolinone derivatives and their use as therapeutic agents EXELIXIS, INC. (US) 2007-09-04 US disclosed
US-20040204447-A1 Isoquinolinone derivatives and their use as therapeutic agents X-CEPTOR THERAPEUTICS INC. 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132521-A1 Isoquinolinone Derivatives and Their Use As Therapeutic Agents NR1H2, NR1H3, NR1I2 RXRA 25/4885NR1H2 1/4885NR1H3 2/4885
US-20040204447-A1 Isoquinolinone derivatives and their use as therapeutic agents NR1H2, NR1I2, NR1H3 RXRA 17/4885NR1H2 1/4885NR1H3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.